3 potentially overvalued FTSE stocks I’d still consider buying on a dip

Some recent stock market successes for UK companies have resulted in over-inflated stock prices. I look at three worth watching in 2020.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

While worldwide worries have prevented many stocks from thriving in 2019, a select few have defied expectations and done extremely well. Positive sentiment drives buyers to these stocks, but it can also result in them becoming overvalued, when they become too expensive for their own good.

I think this is the case for several such successes in recent months, but there are still a few I’d take my chances with, particularly if the share price drops.

From the FTSE 100, I’d choose global pharmaceutical giant Astrazeneca (LSE:AZN), while from the FTSE 250, I’d choose Future (LSE:FUTR), an international media group and digital publisher, and JD Sports Fashion, the sports retailer.

Health for wealth

Astrazeneca has had an exceptionally good year. Its share price has risen over 27% since January.  This is thanks to several positive developments in its drug research and commercialisation.

It specialises in the treatment of diseases in the areas of oncology, cardiovascular, renal and metabolism, and respiratory.

November alone was impressive. Its drug Imfinzi was granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer, an aggressive, fast-growing form of lung cancer. Calquence, a leukaemia drug, was approved in the US for adult patients, Qtrilmet was approved in the EU for the treatment of type-2 diabetes, and the FDA accepted a New Drug Application and granted Priority Review for Selumetinib, as a potential new medicine for paediatric patients with NF1, a rare and incurable genetic condition.

This pharma favourite has a trailing price-to-earnings ratio (P/E) of 47 and its dividend yield is 2.9%. Earnings per share are £1.31 and its debt ratio is 68%.

Future returns

Customer loyalty has contributed to record revenue growth for Future and according to the London Stock Exchange, its e-commerce clicks soared 44% year-on-year following Black Friday 2019.

This publishing giant’s top online properties include technology sites TechRadar, GamesRadar, and Tom’s Guide. Leading products advertised and sold through these sites on Black Friday included Google’s Pixel 4 smartphone, and the Sony Playstation VR, as well as subscriptions to streaming services such as Hulu and Disney+.

The relevance and trusted nature of these sites give consumers the confidence to shop online as the sites offer expert buying advice across consumer categories such as tech, games, music, homes, and more.

Future has recently announced two major acquisitions; a £140m acquisition of TI Media, a UK-based print-let consumer magazine and digital publisher with brands such as Marie Claire and World Soccer. This preceded the £23.5m acquisition of Barcroft Studios, creator of digital video and television content.

Future has an astronomical trailing P/E of 138. Its dividend yield is a very low 0.14% but the cover is more than 10 times. Earnings per share are 9p and its debt ratio is a low 12%.

Sporting hero

JD Sports Fashion has a P/E of 28, so not as high as the previous two. Its dividend yield is a very low 0.22% but it has a dividend cover of 15 times, which means it could increase if the company continues to thrive. Earnings per share are 26p.

It’s important to note that these stocks are currently overvalued, so I think they’re worth watching for the possibility to buy on a dip, but I wouldn’t rush out and buy them at today’s prices.

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature black woman at home texting on her cell phone while sitting on the couch
Investing Articles

Want a £1m Stocks and Shares ISA? Step 1 starts before 5 April

Dr James Fox explains why the Stocks and Shares ISA is an incredible vehicle, and why investors may want to…

Read more »

Happy woman commuting on a train and checking her mobile phone while using headphones
Investing Articles

2 dirt-cheap stocks to consider buying for an ISA portfolio in April

This pair of UK shares are down by double digits in recent months. Ben McPoland sees both as stocks to…

Read more »

Front view photo of a woman using digital tablet in London
Growth Shares

I think this undervalued penny stock has serious potential to outperform

Jon Smith points out a penny stock that's started to rise as the company pushes ahead with a transformation that…

Read more »

Close-up of children holding a planet at the beach
Investing Articles

2 dividend-paying investment trusts to consider for a Stocks and Shares ISA

These two London-listed funds source their dividends globally, offering income investors diversification inside an ISA portfolio.

Read more »

Businesswoman calculating finances in an office
Investing Articles

Waiting for a stock market crash? This FTSE 100 superstar just fell 19% in a day

A stock market crash can be a great time to buy shares. But one of the FTSE 100’s leading lights…

Read more »

Road trip. Father and son travelling together by car
Investing Articles

Rolls-Royce shares down 19%. Why is this major broker still as bullish as ever?

Our writer looks into the long-term investment case for Rolls-Royce shares after a 19% dip, and finds at least one…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

9% yield! But a cut’s coming for 1 of the UK’s most reliable dividend stocks

While other housebuilding stocks have had big dividend cuts in recent years, Taylor Wimpey's been incredibly resilient. But that's set…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Stock market crash? 1 Nasdaq share I’m keeping an eye on

With the stock market taking the elevator down recently, out writer has his eye on a company hoping to compete…

Read more »